About Us

We bring deep expertise in veterinary medicine, clinical pharmacy, cutting‑edge drug‑formulation research, and high‑precision formulation and manufacturing.
Enabling faster, safer and more tailored therapeutic solutions.

Susanne Bredenberg

Chief Executive Officer
Head of Production

PhD in Pharmaceutics and Executive MBA, Stockholm School of Economics. Over 25 years of experience of product development from innovation to market, such as formulation development, clinical trials, manufacturing and business development. Has founded 2 company

Mattias Paulsson

Head of QA 
Member of the Board, Co-founder

A licensed pharmacist and Associate Professor in Clinical Pharmacy. Since 2015, he has been a pioneer in implementing 3D-printed medicines for extemporaneous manufacturing in human medicine. Has founded 2 companies.  

Christel Bergström

Chairman of the Board
Chief Scientific Officer, Co-founder

Professor of Molecular Pharmaceutics at Uppsala University, and an internationally recognized leader in pharmaceutical formulation. With over 25 years of experience, Christel brings unparalleled expertise and a global network spanning academia and industry. Has founded 4 companies. 

Henrik Rönnberg

 Chief Medical Officer, Co-founder

Professor of  Veterinary Pharmacology, DiplECVIM-CA (Oncology) at the Swedish University of Agricultural Sciences. Henrik is a world renowned expert in comparative clinical oncology with over 25 years of research experience and significant contributions to veterinary and human clinical trials. Founded 3 companies.

Sverre Bengtsson

 Member of the Board

Sverre Bengtsson is a life science veteran with more than 30 years of experience in the life science industry. Sverre co-founded the software company Viedoc Technologies, the company behind the groundbreaking, smart, and feature-rich eClinical system Viedoc. He is also an active angel investor, having invested in roughly 30 life science companies.
Extem Pharma AB

News and Updates

Welcome to our news section! Here you will find the latest updates from Extem Pharma.

Susanne Bredenberg, June 2, 2026

IVA’s List for Research Impact 2026

Extem Pharma has been selected for IVA’s List for Research Impact 2026 with the project “Agile pharmaceutical production by 3D printing”. Based on research from Uppsala University, Extem Pharma is working to develop flexible and personalised pharmaceutical manufacturing using 3D printing. We are proud that this work has been recognised by IVA as a research-based innovation with strong potential for societal benefit and practical application.

Please see link below for the more information IVA's list

Questions? Please contact us on information@extempharma.com

Susanne Bredenberg, May 15, 2026

New publication on 3D-printed clonazepam tablets.

Researchers at Uppsala University including Extem Pharma founders have published a new study on the development of 3D-printed clonazepam tablets. Clonazepam is a compound where flexible dosing is important, particularly for children.

The work shows that solid 3D-printed tablets could be produced even with high lipid content, included to improve drug loading and delivery of this poorly water-soluble compound. The tablets also complied with relevant pharmacopoeial quality attributes.

For Extem Pharma, this type of research forms an important foundation for future work with flexible and patient-adapted pharmaceutical manufacturing.

Please see the complete article in Link to paper

Questions? Please contact us on information@extempharma.com

Susanne Bredenberg, May 1, 2026

EXTEM® is now a registered trade mark

We are pleased to share that the European Union Intellectual Property Office has issued a certificate of registration for the European Union trade mark EXTEM (number 019295262).


Questions? Please contact us on information@extempharma.com

Susanne Bredenberg, May 5, 2026

New research article on sustainable 3D printing of veterinary gabapentin tablets

We are pleased to share that two of our founders have published their latest research in the article “Reusable Gelatin-Based Inks for 3D Printing of Veterinary Gabapentin Tablets". The study highlights how reusable pharma inks can be used in semi-solid extrusion 3D printing of personalised veterinary tablets, with potential to reduce resource use and simplify manufacturing.

Please see link below for the complete article in Frontiers in Veterinary Science:

Reusable Gelatin-Based Inks for 3D Printing of Veterinary Gabapentin Tablets: A Sustainable Approach

Questions? Please contact us on information@extempharma.com

Susanne Bredenberg, Apr 17, 2026

Extem Pharma is the winner in “Future Outlook of the Year” at the Uppsala Business Gala

We are proud to share that Extem Pharma has received the Future Outlook of the Year award at the Uppsala Entrepreneurial Gala 2026.

Being nominated in such strong competition was already an honour, and winning the award makes us even more motivated to continue developing Extem Pharma and delivering tailored solutions for formulation and manufacturing needs.

Questions? Please contact us on information@extempharma.com

Mattias Paulsson, Jan16, 2026

Extem Pharma has a new logo



Questions? Please contact us on information@extempharma.com

Mattias Paulsson, Dec 18, 2025

Extem Pharma has been awarded the Attractive Innovation prize by UU Innovation for our platform enabling individualized solid dosage medicines using 3D printing.


Read more here: AIP 2025 – Research – Staff – Uppsala University

Questions? Please contact us on information@extempharma.com

Mattias Paulsson, Oct 29, 2025

Extem Pharma has been awarded funding from Vinnova - Sweden's Innovation Agency for our project "Rapid and flexible batch production of medicines for early clinical trails"


This recognition highlights the strong innovation potential of our 3D-printed medicines and our mission to accelerate access to high-quality clinical trial materials.
We are proud to contribute to the future of pharmaceutical manufacturing in Sweden as an innovative startup company.

Questions? Please contact us on information@extempharma.com



Mattias Paulsson, Sep 20, 2025

Successful Completion of Seed Round

Extem Pharma has successfully completed its directed share issue. The round was fully subscribed, marking an important step in accelerating the build-up of our production site and advancing our business development.

Questions? Please contact us on information@extempharma.com

Mattias Paulsson, Aug 2025

Explaining 3D-Printed Drugs: Extem Pharma founders on Swedish Television

At our company, two of our founders were recently featured on Swedish public television (SVT), showcasing 3D‑printing for on‑demand, customized pharmaceuticals. From lab‑made “vanilla” to “tuna‑flavored” medicines, this technology makes it possible to design doses and flavours that match the individual patient needs.

Vanilj eller tonfisk – här i labbet skapas 3D-printade läkemedel | SVT Nyheter

Mattias Paulsson, July 2025

Extem Pharma has now secured its production facility

Extem Pharma has signed a lease agreement for its first manufacturing site, located at Vallongatan 1 in Uppsala. The facility will be equipped for GMP-compliant small-scale pharmaceutical production and 3D printing of personalised medicines.

Mattias Paulsson, July 2025

Safer Medicines for Children – Powered by 3D Printing

Up to 37% of oral drugs given to children are manipulated before use — split, crushed, or dispersed — leading to dosing errors and safety risks.

One of our co-founders is the lead author of a recent scientific review highlighting these challenges and the need for personalised manufacturing in paediatrics.

Challenges and Considerations in Manipulating Oral Dosage Forms in Paediatric Healthcare Settings: A Narrative Review - Paulsson - Acta Paediatrica - Wiley Online Library

Extem Pharma offers a better way: age-appropriate, 3D-printed medicines tailored to each patient.



Mattias Paulsson, May 2025

Extem Pharma, Uppsala and Craft Health, Singapore embark on strategic partnership

We’re so happy to announce our collaboration with Craft Health, a pioneering company based in Singapore specializing in 3D printing of pharmaceuticals.

This partnership strengthens Extem Pharma’s commitment to personalized medicine and supports our mission to bring innovative, patient-friendly drug formulations to the market.

Together, we aim to accelerate the development and adoption of 3D-printed dosage forms in clinical practice. Please read more about Craft Health here.

Questions? Please contact us on information@extempharma.com

Mattias Paulsson, March 2025

The company turns one and is awarded the Bona Postulata price! 🥳

One year ago, we officially launched Extem Pharma - and what a year it's been!  We are also proud to announce that we have been awarded the Business Prize Bona Postulata! Thank you to everyone who has supported on this journey!

The Science Behind

Extem Pharma was founded by researchers with a strong background in pharmaceutical sciences, veterinary medicine and drug formulation. To learn more about our scientific contributions, you can explore the scientist's publication lists below.

Mattias Paulsson

View his Uppsala University site here

Christel Bergström

View her Uppsala University site here

Henrik Rönnberg

View his Orcid site here